<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00628121</url>
  </required_header>
  <id_info>
    <org_study_id>9575A402</org_study_id>
    <nct_id>NCT00628121</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacological Study of GnRH Antagonist, Cetrorelix for Healthy Female Volunteer</brief_title>
  <official_title>Clinical Pharmacological Study of NS75A for Healthy Adult Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nippon Kayaku Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AEterna Zentaris</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nippon Kayaku Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GnRH analogs are globally used for assisted reproduction in infertile patients. To date, in
      healthy female volunteers the pharmacokinetic and pharmacodynamic profiles of cetrorelix when
      administered in a single dose have been investigated in studies conducted using doses of 1, 3
      and 5 mg. Studies performed in premenopausal female volunteers confirmed that cetrorelix
      rapidly suppresses luteinizing hormone (LH) and estradiol and shows dose-dependent
      prolongation of the duration of LH suppression. However, there have been few reports of
      studies of the relationship between the cetrorelix dosage and its effect on LH surge. In the
      present study, we investigated the effect of cetrorelix on LH surge when this drug was
      administered in single doses of 1, 2 and 3 mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate that effect on LH surge, we investigated the efficacy of cetrorelix in delaying
      the start of the LH surge in comparison with the control menstrual cycle when saline was
      administered, and also examined the mode of disappearance of pulsatile LH secretion during
      the cetrorelix administration menstrual cycle.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Day of the LH surge</measure>
    <time_frame>Saline administration menstrual cycle, cetrorelix administration menstrual cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum LH concentrations</measure>
    <time_frame>Saline administration menstrual cycle, cetrorelix administration menstrual cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Premenopause</condition>
  <arm_group>
    <arm_group_label>Cetrorelix 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetrorelix 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetrorelix 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrorelix</intervention_name>
    <description>1, 2 or 3mg, subcutaneouly dosed with single dose</description>
    <arm_group_label>Cetrorelix 1 mg</arm_group_label>
    <arm_group_label>Cetrorelix 2 mg</arm_group_label>
    <arm_group_label>Cetrorelix 3 mg</arm_group_label>
    <other_name>NS75A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a BMI of 18 years old and &lt;18 and 25 years old and &gt;25

          -  menstrual cycles was within the range of 25~31 days

        Exclusion Criteria:

          -  use of a drug (e.g., oral contraceptives, drugs for treatment of hyperprolactinemia,
             GnRH agonists, sex steroid hormones, psychoactive drugs, etc.)

          -  serious disease of the endocrine system, liver, kidney, heart, lung, digestive system,
             etc.

          -  a generalized drug allergy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kitasato University East Hospital</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>228-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2008</study_first_submitted>
  <study_first_submitted_qc>February 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2008</study_first_posted>
  <last_update_submitted>February 25, 2008</last_update_submitted>
  <last_update_submitted_qc>February 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Nippon Kayaku Co., Ltd.</name_title>
  </responsible_party>
  <keyword>infertility, menstrual cycle, LH surge</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetrorelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

